BBIO

Bridgebio Pharma

• TipRanks·3h ago

  BridgeBio initiated with an Outperform at RBC Capital

• Simply Wall St·6d ago

  A Look At BridgeBio Pharma (BBIO) Valuation After BBP-418 NDA And New Acoramidis Data

• TipRanks·03/31 14:20

  Analysts Offer Insights on Healthcare Companies: Danaher (DHR), 60 Degrees Pharmaceuticals, Inc. (SXTP) and BridgeBio Pharma (BBIO)

• TipRanks·03/31 11:01

  Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

• TipRanks·03/31 10:37

  BridgeBio: Advancing First-in-Class LGMD Therapy and Blockbuster ATTR Franchise Underpin Reiterated Buy and $100 Target

• TipRanks·03/30 23:50

  BridgeBio Files NDA for LGMD2I/R9 Oral Therapy

• Reuters·03/30 19:48

  BridgeBio presentation shows acoramidis cuts all-cause mortality risk 45% in ATTR-CM trial extension

• TipRanks·03/30 19:40

  BridgeBio presents long-term efficacy, safety data from ATTRibute-CM trial

• Benzinga·03/30 19:34

  BridgeBio Pharma's Data From ATTRibute-CM Open-Label Extension Study Shows 44.7% Reduction In All-Cause Mortality, 49.3% In Cardiovascular Mortality Versus Placebo-To-Acoramidis; Acoramidis Well-Tolerated With No Long-Term Safety Concerns

• Reuters·03/30 19:30

  BridgeBio says acoramidis cuts all-cause mortality 44.7% in ATTR-CM extension study

• Reuters·03/30 15:34

  BridgeBio presents acoramidis data linking early sTTR rise to better KCCQ outcomes in ATTR-CM

• Reuters·03/30 15:34

  BridgeBio presents long-term acoramidis data showing sustained sTTR gains, stable KCCQ scores

• Reuters·03/30 15:34

  BridgeBio presents US survey showing high ATTR-CM treatment dissatisfaction, oral dosing preferred

• TipRanks·03/30 14:10

  Analysts’ Top Healthcare Picks: Xtant Medical Holdings (XTNT), Innovent Biologics (IVBXF)

• Reuters·03/30 11:32

  BridgeBio submits FDA NDA for BBP-418 in LGMD2I/R9